Human immunoglobulin with recombinant human hyaluronidase maintenance therapy for treating multifocal motor neuropathy

Human immunoglobulin with recombinant human hyaluronidase is currently in development for the maintenance treatment of patients with multifocal motor neuropathy (MMN). MMN is a rare disease that causes damage to the nerves in the arms and legs. The nerve damage is progressive and worsens over time. The cause of MMN is unknown, but it is thought to be due to an abnormal immune response. The main treatment option for MMN is immunoglobulin therapy. Treatment usually does not completely reverse all the symptoms, and those patients who do respond will require repeated treatments to maintain their improvement.
Human immunoglobulin with recombinant human hyaluronidase